← All Annovis Bio, INC filings

Annovis Bio, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
ANVS
Annovis Bio, INC
10-K: Annovis Bio's Buntanetap Advances in AD, PD Trials; Faces Going Concern
Annovis Bio reports progress in its pivotal Phase 3 Alzheimer's and Open-Label Extension Parkinson's trials for buntanetap, while acknowledging substantial doubt about its ability to continue as a going concern without additional financing.
NYSE
ANVS
Annovis Bio, INC
10-K: Annovis Bio Faces Going Concern Doubts Despite Promising Clinical Data in Alzheimer's and Parkinson's
Annovis Bio reports positive clinical trial results for buntanetap in treating neurodegenerative diseases but acknowledges substantial doubt about its ability to continue as a going concern due to recurring losses.
NYSE
ANVS
Annovis Bio, INC
10-K: Annovis Bio Details Capital Structure and Stockholder Rights in 10-K Filing
Annovis Bio's 10-K filing outlines the company's capital structure, including common and preferred stock details, registration rights, and anti-takeover provisions.